Browsing Tag
Ascletis Pharma Inc.
6 posts
Ascletis Pharma advances ASC36 into clinical development, betting on oral amylin peptides for obesity
Ascletis Pharma Inc. moves ASC36 into clinical development, signalling a strategic push into oral amylin peptides for obesity. Find out what this means next.
Can Ascletis’ obesity pipeline redefine oral and monthly peptide therapy in 2026?
Find out how Ascletis’ oral and monthly obesity therapies are challenging industry norms with next-gen peptide technology.
Why investors are watching Ascletis Pharma’s monthly obesity shot as a potential GLP-1 disruptor
Ascletis Pharma reveals ASC36–ASC35 obesity combo with 51% greater weight loss vs tirzepatide. IND filing expected in 2026. Learn what’s next in its pipeline.
Denifanstat phase 3 acne trial success positions Ascletis for China NDA submission in 2026
Find out how Denifanstat’s Phase 3 acne trial success positions Ascletis Pharma for a 2026 China NDA submission and reshapes the acne-therapy market.
Is Ascletis Pharma quietly building an Asian obesity pipeline rival to Novo Nordisk and Eli Lilly?
Ascletis Pharma is building an obesity pipeline with ASC47 and ASC30. Can this dual-pathway approach rival Novo Nordisk and Eli Lilly?
Ascletis Pharma completes dosing in U.S. ASC47-semaglutide study for obesity treatment
Ascletis Pharma completes dosing in its ASC47-semaglutide obesity trial. Find out why Q4 2025 data could be a game changer for muscle-preserving weight loss.